{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:50:35Z","timestamp":1780588235448,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,29]]},"DOI":"10.7759\/cureus.25444","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:59:07Z","timestamp":1653825547000},"source":"Crossref","is-referenced-by-count":3,"title":["Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia Syndrome as a Clinical Profile Leading to the Diagnosis of Transthyretin Amyloidosis: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Koji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Sakaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.05.001","article-title":"BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia","volume":"59","author":"Farkas JD","year":"2020","unstructured":"Farkas JD, Long B, Koyfman A, Menson K. BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia. J Emerg Med. 2020, 59:216-23. 10.1016\/j.jemermed.2020.05.001","journal-title":"J Emerg Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021, 42:1554-68. 10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias ED","year":"2017","unstructured":"Pagourelias ED, Mirea O, Duchenne J, et al.. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017, 10:e005588. 10.1161\/CIRCIMAGING.116.005588","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss JN","year":"2017","unstructured":"Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017, 10:e004667. 10.1161\/CIRCEP.116.004667","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2015.07.017","article-title":"European Resuscitation Council Guidelines for Resuscitation 2015. Section 4. Cardiac arrest in special circumstances","volume":"95","author":"Truhl\u00e1\u0159 A","year":"2015","unstructured":"Truhl\u00e1\u0159 A, Deakin CD, Soar J, et al.. European Resuscitation Council Guidelines for Resuscitation 2015. Section 4. Cardiac arrest in special circumstances. Resuscitation. 2015, 95:148-201. 10.1016\/j.resuscitation.2015.07.017","journal-title":"Resuscitation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2021.01.033","article-title":"BRASH syndrome: a case report","volume":"60","author":"Vishnu VK","year":"2021","unstructured":"Vishnu VK, Jamshed N, Amrithanand VT, Thandar S. BRASH syndrome: a case report. J Emerg Med. 2021, 60:818-22. 10.1016\/j.jemermed.2021.01.033","journal-title":"J Emerg Med"},{"key":"ref8","article-title":"Verapamil deleterious effects in chronic renal failure","volume":"72","author":"V\u00e1quez C","year":"1996","unstructured":"V\u00e1quez C, Huelmos A, Alegr\u00eda E, Errasti P, Purroy A. Verapamil deleterious effects in chronic renal failure. Nephron. 1996, 72:461-4.","journal-title":"Nephron"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938010-00003","article-title":"Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension","volume":"38","author":"McTavish D","year":"1989","unstructured":"McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989, 38:19-76. 10.2165\/00003495-198938010-00003","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426050-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of carvedilol","volume":"26","author":"Morgan T","year":"1994","unstructured":"Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994, 26:335-46. 10.2165\/00003088-199426050-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11604\/pamj-cm.2020.4.128.27304","article-title":"BRASH syndrome: an emerging emergency","volume":"4","author":"Chothia M-Y","year":"2020","unstructured":"Chothia M-Y, Davids MR. BRASH syndrome: an emerging emergency. PAMJ-CM. 2020, 4:10.11604\/pamj-cm.2020.4.128.27304","journal-title":"PAMJ-CM"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-16-3-241","article-title":"BRASH syndrome with hyperkalemia: an under-recognized clinical condition","volume":"16","author":"Arif AW","year":"2020","unstructured":"Arif AW, Khan MS, Masri A, Mba B, Talha Ayub M, Doukky R. BRASH syndrome with hyperkalemia: an under-recognized clinical condition. Methodist Debakey Cardiovasc J. 2020, 16:241-4. 10.14797\/mdcj-16-3-241","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref13","unstructured":"Amlodipine besylate tablets. (2007). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/019787s042lbl.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90269-0","article-title":"An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension","volume":"73","author":"Abernethy DR","year":"1994","unstructured":"Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol. 1994, 73:10-7. 10.1016\/0002-9149(94)90269-0","journal-title":"Am J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka H","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, et al.. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020, 84:1610-71. 10.1253\/circj.CJ-20-0110","journal-title":"Circ J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-021-02890-6","article-title":"Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis","author":"Takahashi K","year":"2021","unstructured":"Takahashi K, Sasaki D, Yamashita M, et al.. Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2021, 10.1007\/s12350-021-02890-6","journal-title":"J Nucl Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn I","year":"2019","unstructured":"Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H. Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. Cardiol Ther. 2019, 8:297-316. 10.1007\/s40119-019-0142-5","journal-title":"Cardiol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249420","article-title":"Congestive hepatopathy","volume":"21","author":"Fortea JI","year":"2020","unstructured":"Fortea JI, Puente \u00c1, Cuadrado A, et al.. Congestive hepatopathy. Int J Mol Sci. 2020, 21:9420. 10.3390\/ijms21249420","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt DF","year":"2014","unstructured":"Hutt DF, Quigley AM, Page J, et al.. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014, 15:1289-98. 10.1093\/ehjci\/jeu107","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95551-bradycardia-renal-failure-atrioventricular-nodal-blockade-shock-and-hyperkalemia-syndrome-as-a-clinical-profile-leading-to-the-diagnosis-of-transthyretin-amyloidosis-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:00Z","timestamp":1707507360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95551-bradycardia-renal-failure-atrioventricular-nodal-blockade-shock-and-hyperkalemia-syndrome-as-a-clinical-profile-leading-to-the-diagnosis-of-transthyretin-amyloidosis-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.25444","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}